Loading stock data…
$2.06-0.04 (-2.13%)
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa.
Seer, Inc. in the Healthcare sector is trading at $2.06 with a market capitalization of $121M. Wall Street consensus targets $4.00 (1 analysts), implying a +93.7% move over the next 12 months. The stock is currently 14% below its 52-week high of $2.41, remaining 7.6% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $3.00M↑ | $2.71M↓ | $4.07M↑ | $3.97M↑ | $3.93M |
| Gross Profit | $1.41M↑ | $895,000↓ | $2.06M↑ | $1.96M↓ | $1.99M |
| Operating Income | -$16.84M↑ | -$17.26M↑ | -$17.39M↑ | -$19.35M↑ | -$20.53M |
| Net Income | -$16.90M↓ | -$16.84M↓ | -$15.99M↑ | -$18.23M↑ | -$19.42M |
Seer, Inc., a life sciences company, develops and commercializes products to decode the biology of the proteome to improve human health in the United States, China, Australia, Europe, Israel, Japan, and South Africa. The company offers Proteograph Pr...